Krishna Institute of Medical Sciences Ltd
Krishna Institute of Medical Sciences Q2 Results 2026 (FY27) investor presentation: Revenue & Margins
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
Get Krishna Institute of Medical Sciences Ltd's next results in your feed
Guidance rank: #29 of 32 in Healthcare Services
See the sector's top 10 — free with your mobile number.
Based on Krishna Institute of Medical Sciences Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q2 FY27 Total Revenue: Rs. 13,630 million, up 41.3% YoY (Q2 FY26: Rs. 9,649 million). EBITDA for Q2 FY27: Rs. 2,789 million.
From Krishna Institute of Medical Sciences Ltd's Q2 FY27 earnings-call transcript · updated 4 Nov 2026.
How did Krishna Institute of Medical Sciences' revenue grow in the September 2026 quarter?
- Q2 FY27 Total Revenue: Rs. 13,630 million, up 41.3% YoY (Q2 FY26: Rs. 9,649 million)
- Operating Revenue for Q2 FY27: Rs. 13,444 million, up 39.9% YoY (Q2 FY26: Rs. 9,607 million)
- IP Volume for Q2 FY27: 81,668, up 27.0% YoY (Q2 FY26: 64,288)
- OP Volume for Q2 FY27: 731,010, up 23.3% YoY (Q2 FY26: 592,725)
2 more points from Krishna Institute of Medical Sciences Ltd's call on revenue
Create a free account to keep reading this call
What happened to Krishna Institute of Medical Sciences' margins in Q2 FY27?
See what Krishna Institute of Medical Sciences Ltd said on profitability & margins — free account, 30 seconds.
What capex is Krishna Institute of Medical Sciences planning?
- Adding 700+ beds through Greenfield projects, acquisitions, and Operations & Maintenance (O&M) opportunities (Page 15).
- Secunderabad unit has a total bed capacity of 1,000 beds: 750 operational and 250 under construction (Pages 22, 24, 30).
- Electronic City (Bengaluru) and Mahadevapura (Bengaluru) units ramping up, with NABH accreditation achieved and EBITDA turning positive in Q2 FY27 (Page 27).
- Secured Liver & Kidney Transplant Licenses, enhancing tertiary care capabilities, with first transplants successfully performed (Page 27).
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Krishna Institute of Medical Sciences raising money or cutting debt?
See what Krishna Institute of Medical Sciences Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Krishna Institute of Medical Sciences' order book?
See what Krishna Institute of Medical Sciences Ltd said on order book & pipeline — free account, 30 seconds.
Krishna Institute of Medical Sciences Ltd — Quarterly revenue & net profit
Q2 FY27 figures are not in this chart yet. Latest shown: Jun 2026 (Q1 FY27). The Q2 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q1 FY27): revenue ₹1.2K Cr, net profit ₹37 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Krishna Institute of Medical Sciences's management said in earlier quarters
Others in Healthcare Services this season
- Gujarat Kidney (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹3,809 lakhs, +195% YoY (Page 6, 7) . Key investor presentation takeaways from Gujarat Kidney & Super Speciality Ltd's Q2 FY27
- Apollo Hospitals (Q2 FY27)
Q2 FY27 Revenue: ₹76,149 million (Consolidated), up 23% YoY from ₹61,888 million in Q2 FY26. Key investor presentation takeaways from Apollo Hospitals Enterpris
- Vimta Labs (Q2 FY27)
Export-import linked food testing volumes recovering with operations reaching 60%-70% of normal levels. Key concall takeaways from Vimta Labs Ltd's Q2 FY27…
- Dr Lal Pathlabs Ltd (Q2 FY27)
874 Cr, up 19.6% YoY from Rs. Key investor presentation takeaways from Dr Lal Pathlabs Ltd's Q2 FY27 investor presentation — and how it ranks against sector pee
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- Aster DM Quality Care LtdGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Krishna Institute of Medical Sciences Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Krishna Institute of Medical Sciences Ltd Q2 FY27 results?
Q2 FY27 Total Revenue: Rs. 13,630 million, up 41.3% YoY (Q2 FY26: Rs. 9,649 million). EBITDA for Q2 FY27: Rs. 2,789 million.
What is Krishna Institute of Medical Sciences Ltd share price analysis?
Krishna Institute of Medical Sciences Ltd currently shows a neutral. The stock trades at a P/E of 149.1 with a market cap of ₹31,085 Cr. Investors should review the full earnings analysis for detailed insights.
Is Krishna Institute of Medical Sciences Ltd planning capital expenditure?
Adding 700+ beds through Greenfield projects, acquisitions, and Operations & Maintenance (O&M) opportunities (Page 15).
Keep Krishna Institute of Medical Sciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.